OncoMatch/Clinical Trials/NCT05097209
Camrelizumab for the Treatment of Locally Advanced Nasopharyngeal Carcinoma
Is NCT05097209 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Camrelizumab and Gemcitabine for nasopharyngeal carcinoma.
Treatment: Camrelizumab · Gemcitabine · Induction Cisplatin · Concurrent cisplatin — This trial plans to enroll patients with stage III-IVA (AJCC 8th, included T1-2N2-3 and/or T3-4N0-3 M0) locoregionally-advanced nasopharyngeal carcinoma (LANPC). Patients will be randomized in a 1:1 ratio to receive 3 cycles of induction chemotherapy with gemcitabine and cisplatin and concurrent cisplatin-radiation or 3 cycles of induction chemotherapy with gemcitabine and cisplatin and radiation plus Camrelizumab. All patients will receive intensity-modulated radiotherapy (IMRT). Camrelizumab will begin on day 1 of induction chemotherapy every 3 weeks for 3 cycles and continue every 2 weeks for 9 cycles.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage III, IVA
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
neutrocyte count≥1.5×10e9/l, hemoglobin ≥80g/l, platelet count ≥80×10e9/l
Kidney function
creatinine clearance rate ≥ 60 ml/min (cockcroft-gault formula)
Liver function
alt/ast ≤2.5×uln, bilirubin ≤1.5×uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify